Top Markets
#1 ADO Protocol ADO Protocol +194.18%
#2 Islamic Coin Islamic Coin +155.39%
#3 GoPlus Security GoPlus Security +39.78%
#4 GAIB AID GAIB AID +24.67%
#5 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +19.15%
#6 SkyAI SkyAI +14.37%
#7 TENDIES TENDIES +13.92%
#8 Tutorial Tutorial +13.78%
#9 Verus Coin Verus Coin +13.66%
#10 Pons Pons +12.05%
Coin of the day
ADO Protocol ADO Protocol
Settings
Language
ENGLISH
Currency
USD
Theme
Erika B-Cure Laser Ltd Erika B-Cure Laser Ltd

Erika B-Cure Laser Ltd

BCUR
Rank in Stocks #33765
Erika B-Cure Laser Ltd, established in Haifa, Israel in 2007, is a company... Erika B-Cure Laser Ltd, established in Haifa, Israel in 2007, is a company dedicated to the full lifecycle of its B-Cure laser product line, from development and manufacturing to global marketing, sales, and distribution. Formerly known as Erica Carmel Ltd until its rebranding in January 2022, the company offers a diverse array of laser devices tailored for various therapeutic applications in both domestic and international markets. Their product portfolio includes: The B-Cure Laser Classic, a medical device for home use that addresses a broad spectrum of conditions including general pain, orthopedic issues, dermatological problems, inflammation, and supports wound healing. The B-Cure Laser Pro, designed to treat more severe or chronic ailments such as persistent orthopedic challenges, diabetic wounds, and difficulties in recovery, including mucositis. The B-Cure Laser Sport, a home-based device for managing sports injuries, athletic discomfort, and other orthopedic concerns. The professional-grade B-Cure Laser Sport Pro, which provides advanced treatment for sports-related injuries, pain relief in muscles and various body areas, and helps combat infections like Achilles tendonitis. For dental professionals, the B-Cure Laser Dental is an in-clinic device formulated to tackle a variety of oral health problems, alleviate gum pain and inflammation, expedite recovery post-dental procedures (including implants), and reduce associated swelling and discomfort. Additionally, the B-Pro Dental Laser Cure is available for dental clinics, specifically engineered to address diverse dental issues and infections.
Share Price
$0.06676455
Last synced: 2025-11-10
Market Cap
$6.95M
Change (1 day)
3.25%
Change (1 year)
-19.96%
Country
IL
Trade Erika B-Cure Laser Ltd (BCUR)

Category

Healthcare
P/E ratio for Erika B-Cure Laser Ltd (BCUR)
P/E ratio as of 2026 TTM: 0
According to Erika B-Cure Laser Ltd latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Erika B-Cure Laser Ltd from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Abbott Laboratories Abbott Laboratories
Abbott Laboratories
ABT.US
 35.77 -
US
Stryker Corporation Stryker Corporation
Stryker Corporation
SYK.US
 34.86 -
US
Medtronic plc Medtronic plc
Medtronic plc
MDT.US
 21.39 -
IE
Boston Scientific Corporation Boston Scientific Corporation
Boston Scientific Corporation
BSX.US
 20.90 -
US
Edwards Lifesciences Corporation Edwards Lifesciences Corporation
Edwards Lifesciences Corporation
EW.US
 52.64 -
US
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.